Ensho Therapeutics, Inc.
About Ensho Therapeutics, Inc.
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for inflammatory bowel disease (IBD), a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. The company was launched with a Phase 2-ready oral α4β7 inhibitor for IBD and ulcerative colitis.
- 🔗 Healthcare Private Placement and M&A Transactions Review Week Ending September 14, 2025 | Silverwood Partners
- 🔗 Ensho Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations
- 🔗 Ensho Therapeutics - 2026 Funding Rounds & List of Investors - Tracxn
- 🔗 Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho Therapeutics
- 🔗 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease | Ensho Therapeutics
Key highlights
- Raised $22.5M in debt financing on September 12, 2025 from undisclosed investors.
- Acquired oral α4β7 integrin inhibitor portfolio from EA Pharma, a subsidiary of Eisai.
- Launched as a clinical-stage company with a Phase 2-ready asset for IBD and ulcerative colitis.
- Investors include Avego Bioscience Capital and Global BioAccess Fund.
- Headquartered in New Jersey with focus on oral small molecule therapies for inflammatory diseases.
Ask StreetZero about Ensho Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account